Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Several matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been implicated in the development and outcome of coronary artery disease (CAD). We investigated whether MMP-12 and TIMP-1 levels were associated with risk, severity, and outcome of CAD. Plasma MMP-12 and TIMP-1 levels are measured in 50 and 44 patients with CAD, respectively, by enzyme-linked immunosorbent assay. Of all patients, 16 were taking statins. Patients who were not on statins were classified into 3 groups according to number of >50% stenotic vessels. Compared with 29 volunteers without CAD, patients without statins (n = 34) had higher MMP-12 concentrations (1.71 vs 1.08 ng/ml, p = 0.021). MMP-12 levels were significantly lower in patients with than in those without statin treatment (0.99 vs 1.71 ng/ml, p = 0.008). There was no association between MMP-12 levels and number of >50% stenotic vessels. MMP-12 concentrations were not associated with outcome of CAD. However, plasma TIMP-1 levels were associated with restenosis independently of number of stenotic vessels and age (p = 0.035) but not with risk or severity of CAD. In conclusion, plasma MMP-12 concentration was associated with the presence of CAD. Statin therapy decreases plasma MMP-12 levels in patients with CAD. Increased TIMP-1 levels may prevent restenosis after angioplasty.
Jguirim-Souissi
Imen
I
Unit of Research, Genetic and Biologic Factors of Atherosclerosis, Faculty of Medicine, CHU Fattouma, Bourguiba, Monastir, Tunisia.
Jelassi
Awatef
A
Addad
Faouzi
F
Hassine
Majed
M
Najah
Mohamed
M
Ben Hamda
Khaldoun
K
Maatouk
Faouzi
F
Ben Farhat
Mohamed
M
Bouslema
Ali
A
Rouis
Mustapha
M
Slimane
Mohamed Naceur
MN
D000328:Adult; D000368:Aged; D015415:Biomarkers; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D053508:Matrix Metalloproteinase 12 / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019715:Tissue Inhibitor of Metalloproteinase-1; D053508:Matrix Metalloproteinase 12